GlassScriptPhysician profile
Randall J Reed
NPI 1619925757
$7,357.55
in general payments reported to CMS, 2019-2025
37 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,774 · 2020: $782 · 2021: $337 · 2022: $373 · 2023: $533 · 2024: $544 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.35 |
| Education | $227.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.20 | 2019-2025 | |
| Amgen INC. | $814.24 | 2019-2025 | Tavneos, Evenity, Amjevita |
| Ucb, INC. | $558.27 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $524.89 | 2019-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.40 | 2019-2025 | Cyltezo, Ofev, Spevigo |
| Novartis Pharmaceuticals Corporation | $321.50 | 2019-2025 | |
| Horizon Therapeutics Plc | $297.97 | 2019-2023 | Krystexxa |
| Celgene Corporation | $295.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $271.86 | 2020-2025 | Acthar |
| Lilly USA, LLC | $267.53 | 2019-2025 | Taltz |
| Pfizer INC. | $260.70 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $259.61 | 2019-2025 | Orencia |
| Genentech USA, INC. | $236.18 | 2019-2025 | Actemra, Gazyva |
| Janssen Scientific Affairs, LLC | $226.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $210.57 | 2019-2025 | Benlysta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $172.08 | 2021-2025 | Saphnelo |
| Sobi, INC | $165.38 | 2019-2020 | |
| Radius Health, INC. | $164.84 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $153.46 | 2019-2025 | Strensiq, Ultomiris |
| Regeneron Healthcare Solutions, INC. | $128.00 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $92.62 | 2019 | |
| Aurinia Pharma U.S., INC. | $66.84 | 2023-2025 | Lupkynis |
| Kyowa Kirin, INC. | $56.47 | 2025 | |
| Merck Sharp & Dohme LLC | $40.46 | 2019 | |
| Octapharma USA, INC. | $24.90 | 2025 | Octagam Immune Globulin (Human) |
| Medexus Pharma, INC. | $24.26 | 2019 | |
| Genzyme Corporation | $24.16 | 2025 | |
| Tersera Therapeutics LLC | $23.35 | 2019 | |
| Organon LLC | $19.89 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $18.31 | 2024 | Arcalyst |
| Celltrion USA INC. | $17.85 | 2023 | Yuflyma |
| Pacira Pharmaceuticals Incorporated | $16.33 | 2024 | Exparel, Iovera, Zilretta |
| Scilex Pharmaceuticals INC. | $16.14 | 2024 | |
| Gilead Sciences, INC. | $15.98 | 2020 | |
| Antares Pharma, INC. | $15.17 | 2020 | |
| Pacira Therapeutics, INC. | $11.88 | 2019 | |
| Fidia Pharma USA INC. | $3.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.